uniQure (NASDAQ:QURE) Shares Up 12% – Here’s Why

uniQure N.V. (NASDAQ:QURE)’s stock price rose 12% during mid-day trading on Thursday . The stock traded as high as $10.04 and last traded at $10.1250. Approximately 1,648,051 shares changed hands during trading, a decline of 44% from the average daily volume of 2,938,506 shares. The stock had previously closed at $9.04.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Zacks says uniQure is deeply oversold after the selloff and highlights technical and analyst estimate factors that could set the stage for a trend reversal, which could attract short‑term bargain hunters. Zacks: uniQure Loses 67.5% in 4 Weeks
• Neutral Sentiment: Mizuho assigned a Neutral rating on QURE (a non‑directional stance) — this may reduce bullish conviction but is not a hard negative. AmericanBankingNews: Mizuho Neutral
• Negative Sentiment: FDA told uniQure its Huntington’s trial did not provide sufficient evidence the therapy slowed disease progression and requested a new placebo‑controlled study — a major regulatory setback that increases development cost, delays potential approval and raises execution risk. Reuters: FDA official says UniQure fell short
• Negative Sentiment: A wave of securities‑class‑action notices and filings (multiple firms including Faruqi, Bernstein Liebhard, Rosen, Pomerantz, Levi & Korsinsky, Berger Montague and others) target purchases during Sept. 24–Oct. 31, 2025; they flag potential litigation exposure and could pressure investor sentiment and valuation. PR Newswire: Faruqi class action notice
• Negative Sentiment: Multiple analyst actions: Wells Fargo cut QURE from Overweight to Equal Weight and slashed its price target to $15 (from $60); Chardan trimmed its target to $16; Goldman Sachs issued a pessimistic forecast — these lower expectations amplify selling pressure and reduce upside conviction. Benzinga: Wells Fargo downgrade
• Negative Sentiment: News reports of large intraday volume and a multiday selloff (shares near 52‑week lows) indicate momentum is to the downside; that raises the chance of further near‑term volatility. Benzinga: What’s Going On With uniQure Stock

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on QURE shares. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Wolfe Research initiated coverage on shares of uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating for the company. Stifel Nicolaus set a $14.00 price target on shares of uniQure in a research note on Monday. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday. Finally, Barclays began coverage on uniQure in a research note on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, uniQure presently has a consensus rating of “Hold” and a consensus price target of $34.33.

uniQure Stock Performance

The stock has a market cap of $639.24 million, a P/E ratio of -3.03 and a beta of 0.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 7.12. The stock’s 50 day simple moving average is $22.54 and its two-hundred day simple moving average is $29.57.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. As a group, research analysts forecast that uniQure N.V. will post -3.75 EPS for the current year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 12,378 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total transaction of $295,339.08. Following the completion of the transaction, the chief executive officer directly owned 639,076 shares in the company, valued at approximately $15,248,353.36. This trade represents a 1.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the sale, the director owned 20,439 shares in the company, valued at $557,575.92. The trade was a 23.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 50,598 shares of company stock valued at $1,248,588 over the last three months. 4.79% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in QURE. Private Trust Co. NA acquired a new stake in shares of uniQure in the third quarter valued at about $28,000. Torren Management LLC acquired a new position in uniQure during the fourth quarter valued at approximately $28,000. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. IFP Advisors Inc acquired a new position in shares of uniQure during the 4th quarter worth approximately $48,000. Finally, Smartleaf Asset Management LLC bought a new stake in shares of uniQure during the 4th quarter worth approximately $48,000. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.